CAJ | 학술논문

白血病是一种造血干细胞的恶性克隆性疾病。其发病机制与白血病细胞增殖失控、分化障碍、凋亡受阻等有关。研究证实白血病细胞表达CD44，它通过参与细胞黏附、增殖、迁移、浸润等行为促进白血病的发生发展。体外试验表明，以CD44为靶点的治疗能有效杀伤白血病细胞，并降低对正常组织的细胞毒性。因此，针对CD44抗癌药物的设计有望用于白血病的临床治疗。
백혈병시일충조혈간세포적악성극륭성질병。기발병궤제여백혈병세포증식실공、분화장애、조망수조등유관。연구증실백혈병세포표체CD44，타통과삼여세포점부、증식、천이、침윤등행위촉진백혈병적발생발전。체외시험표명，이CD44위파점적치료능유효살상백혈병세포，병강저대정상조직적세포독성。인차，침대CD44항암약물적설계유망용우백혈병적림상치료。
Leukemia is a kind of cloning disease from malignant hematopoietic stem cells. Its patho-genesis may have relationship with proliferation out of control,dysdiffreentiation and inhibition of apoptosis about leukemia cells. The study confirms that CD44 is expressed in leukemia cells,promoting the occurrence and development of leukemia through participation in cell adhension,proliferation,migration and invasion behavior. In vitro experiment shows that CD44 targeted therapies can effectively kill leukemia cells,and reduce the toxicity to normal tissue cells. Therefore,aiming at the design of the anticancer drugs targeted for CD44 is expected to be used in clinical treatment of leukemia.